医学硕士论文参考文献一
1. Siegel, R?，et al?，Cancer statistics, 2014. CA Cancer J Clin，2014. 64(1): p.9-29.
2. Fan, L.，et al., Breast cancer in China. Lancet Oncol, 2014. 15(7): p. e279-89
3. Chambers, A.F.，A.C. Groom，and LC. MacDonald, Dissemination and growthof cancer cells in metastatic sites. Nat Rev Cancer，2002. 2(8); p. 563-72.
4. Christofori, G.，New signals from the invasive front. Nature, 2006. 441(7092):p. 444-50.
5. Gupta, G.R and J. Massague，Cancer metastasis: building a framework. Cell,2006.127(4): p. 679-95.
6. Fidler，I.J.，The pathogenesis of cancer metastasis: the seed and soil’hypothesis revisited. Nat Rev Cancer, 2003. 3(6): p. 453-8.
7. Paget, S.，The distribution of secondary growths in cancer of the breast. 1889.Cancer Metastasis Rev，1989. 8(2): p. 98-101.
8. Edlund, M.，S.Y. Sung, and L.W. Chung, Modulation of prostate cancergrowth in bone microenvironments. J Cell Biochon, 2004. 91(4): p. 686-705.
9. Triozzi，RL.，C. Eng，and A.D. Singh，Targeted therapy for uveal melanoma.Cancer Treat Rev, 2008. 34(3): p. 247-58.
10. Hess, K.R.，et al，Metastatic patterns in adenocarcinoma. Cancer，2006.106(7): p. 1624-33.
11. Patanaphan, V.，O.M. Salazar, and R. Risco, Breast cancer: metastatic patternsand their prognosis. South Med J，1988. 81(9): p. 1109-12.
12. Yin, J.J?，et al., TGF-beta signaling blockade inhibits PTHrP secretion bybreast cancer cells and bone metastases development. J Clin Invest, 1999.103(2): p. 197-206.
13. Minn，AJ.，et al?，Distinct organ-specific metastatic potential of individualbreast cancer cells and primary tumors. J Clin Invest, 2005.115(1): p, 44-55.
14. Schmidt-Kittler, 0., et al” From latent disseminated cells to overt metastasis:genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U SA，2003.100(13): p. 7737-42.
15. Spratt, J.S?，Re: Dormancy of mammary carcinoma after mastectomy. J NatlCancer Inst, 2000. 92(13): p. 1101.
16. Feld，R.，L.V. Rubinstein，and T.H. Weisenberger, Sites of recurrence inresected stage I non-small-cel lung cancer: a guide for future studies. J ClinOncol, 1984. 2(12): p. 1352-8.
17. Hoffinan，RC., A.M. Mauer, and E.E. Yokes, Lung cancer. Lancet, 2000.355(9202): p. 479-85.
18. Minna，J.D.，J.M. Kurie, and T. Jacks, A big step in the study of small cell lungcancer. Cancer Cell, 2003. 4(3): p. 163-6.
19. Klein, C.A” The systemic progression of human cancer: a focus on theindividual disseminated cancer cell—the unit of selection. Adv Cancer Res,2003.89: p. 35-67.
20. Kang, Y?，et al.，A multigenic program mediating breast cancer metastasis tobone. Cancer Cell，2003. 3(6): p. 537-49.
21. Mimdy, G.R., Metastasis to bone: causes, consequences and therapeuticopportunities. Nat Rev Cancer, 2002. 2(8): p. 584-93.
22. Lee, Y.T., Patterns of metastasis and natural courses of breast carcinoma.Cancer Metastasis Rev, 1985, 4(2): p. 153-72.
23. Johansson, J.E., et al., Natural history of early, localized prostate cancer.JAMA, 2004. 291(22): p. 2713-9.
24. Nieto，J.M.Grossbard，and P. Kozuch, Metastatic pancreatic cancer 2008:is the glass less empty? Oncologist, 2008.13(5): p. 562-76.
25. Fearon, E.R. and B. Vogelstein，A genetic model for colorectal tumorigenesis.Cell, 1990. 61(5): p. 759-67.
26. Vogelstein，B.，et al., Genetic alterations during colorectal-tumor development.N Engl J Med, 1988. 319(9): p. 525-32.
27. Samuels, Y” et al,，High frequency of mutations of the PIK3CA gene in humancancers. Science, 2004. 304(5670): p. 554.
28. Baker, SJ., et al., Chromosome 17 deletions and p53 gene mutations incolorectal carcinomas. Science, 1989.244(4901): p. 217-21.
29. Markowitz, S.，et al., Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science，1995. 268(5215): p.1336-8.
30. Jones，S.，et al.，Comparative lesion sequencing provides insights into tumorevolution. Proc Natl Acad Sci USA, 2008.105(11): p. 4283-8.
31. Paku, S., et al. Organ-specificity of the extravasation process: anultrastructural study. Clin Exp Metastasis，2000.18(6): p. 481-92.
32. Lalor，RF.，et al.，Human hepatic sinusoidal endothelial cells can bedistinguished by expression of phenotypic markers related to their specialisedfunctions in vivo. World J Gastroenterol, 2006.12(34): p. 5429-39.
33. Weis, S.，et al., Endothelial barrier disruption by VEGF-mediated Src activitypotentiates tumor cell extravasation and metastasis. J Cell Biol, 2004. 167(2):p. 223-9.
34. Gupta，G.R，et al.，Mediators of vascular remodelling co-opted for sequentialsteps in lung metastasis. Nature, 2007. 446(7137); p. 765-70.
35. Kamoub, A.E., et al., Mesenchymal stem cells within tumour stroma promotebreast cancer metastasis. Nature, 2007. 449(7162): p. 557-63.
36. Padua，D.，et al.，TGFbeta primes breast tumors for lung metastasis seedingthrough angiopoietin-like 4. Cell，2008.133(1); p. 66-77.
37. Weil, RJ., et al., Breast cancer metastasis to the central nervous system. Am JPathol, 2005.167(4): p. 913-20.
38. Kedrin，D.，et al., Cell motility and cytoskeletal regulation in invasion andmetastasis. J MMimiary Gland Biol Neoplasia, 2007.12(2-3): p. 143-52.
39. Weber, G.R, Molecular mechanisms of metastasis. Cancer Lett，2008. 270(2):p. 181-90.
40. Bandyopadhyay, S.，et al” Interaction of KAIl on tumor cells with DARC onvascular endothelium leads to metastasis suppression, Nat Med，2006. 12(8): p.933-8.
医学硕士论文参考文献二
[1] M.R. Prausnitz, S. Mitragotri, R. Langer, Current status and future potential of transdermaldrug delivery, Nature reviews. Drug discovery, 3 (2004) 115-124.
[2] M.A. Miller, E. Pisani, The cost of unsafe injections. Bulletin of the World HealthOrganization, 77 (1999) 808-811.
[3] H.A. Benson，Transdermal drug delivery: penetration enhancement techniques，Current drugdelivery, 2 (2005) 23-33.
[4] D. Lunter, R. Daniels, Confocal Raman microscopic investigation of the effectiveness ofpenetration enhancers for procaine delivery to the skin. Journal of biomedical optics, 19 (2014)126015.
[5] H. Kalluri, A.K, Banga, Transdermal delivery of proteins, AAPS PharmSciTech, 12 (2011)431-441.
[6] C.H. Purdon, C.G, Azzi, J. Zhang, E.W. Smith, H.L Maibach, Penetration enhancement oftransdermal delivery—current permutations and limitations. Critical reviews in therapeuticdrug carrier systems, 21 (2004) 97-132.
[7] X. Pang，X. Yang, G. Zhai, Polymer-drug conjugates: recent progress on administration routes,Expert opinion on drug delivery, 11 (2014) 1075-1086
[8] B.M. Mishriky, A.S. Habib，Nicotine for postoperative analgesia; a systematic review andmeta-analysis, Anesthesia and analgesia, 119 (2014) 268-275.
[9] H. Gupta, RJ. Babu，Transdermal delivery: product and patent update, Recent patents on drugdelivery & formulation, 7 (2013) 184-205.
[10] M. Sugino, H. Todo，K. Sugibayashi, [Skin permeation and transdermal delivery systems ofdrugs: history to overcome barrier function in the stratum comeum], Yakugaku zasshi :Journal of the Pharmaceutical Society of Japan, 129 (2009) 1453-1458.
[11] M.D. Ridge, V. Wright, Mechanical properties of skin: a bioengineering study of skinstructure, Journal of applied physiology, 21 (1966) 1602-1606.
[12] Peptide and protein transdermal drug delivery. Drug discovery today. Technologies, 9 (2012)e71-el74.
[13] H. Li, Y. Yu, S. Faraji Dana, B. Li, C.Y. Lee, L. Kang，Novel engineered systems for oral,mucosal and transdermal drug delivery, Journal of drug taigeting, 21 (2013) 611-629
[14] J.E. Riviere, M.G. Papich, Potential and problems of developing transdermal patches forveterinary applications，Advanced drug delivery reviews, 50 (2001) 175-203.
[15] M.R. Prausnitz, R. Langer, Transdermal drug delivery. Nature biotechnology, 26 (2008)991261-1268.
[16] M. El-Badry, G. Fetih, D. Fathalla, F. Shakeel, Transdermal delivery of meloxicam usingniosomal hydrogels: in vitro and pharmacodynamic evaluation, Pharmaceutical developmentand technology, (2014) 1-7.
[17] K.S. Paudel, M. Milewski, C.L. Swadley, N.K. Brogden, P. Ghosh, A.L. Stinchcomb，Challenges and opportunities in dermal/transdermal delivery, Therapeutic delivery, 1 (2010)109-131.
[18] B.J. Aungst, Absorption enhancers: applications and advances, The AAPS journal, 14 (2012)10-18.
[19] R.K. Subedi，S.Y. Oh, M.K. Chun, H.K. Choi, Recent advances in transdermal drug delivery,Arch Pharm Res, 33 339-351.
[20] S.J. Newton, Chemical penetration enhancers, International journal of pharmaceuticalcompounding, 17 (2013) 370-374.
[21] Y. Chen, M. Wang, L. Fang, Biomaterials as novel penetration enhancers for transdermal anddermal drug delivery systems, Drug delivery, 20 (2013) 199-209.
[22] E.J. Park, J. Werner, N.B. Smith, Ultrasound mediated transdermal insulin delivery in pigsusing a lightweight transducer, Pharmaceutical research, 24 (2007) 1396-1401.
[23] N.B. Smith, S. Lee, K.K. Shung, Ultrasound-mediated transdermal in vivo transport ofinsulin with low-profile cymbal arrays. Ultrasound in medicine & biology, 29 (2003)1205-1210.
[24] T. Gratieri, D. Kalaria, Y.N. Kalia, Non-invasive iontophoretic delivery of peptides andproteins across the skin, Expert opinion on drug delivery, 8 (2011) 645-663.
[25] H. Chen, H. Zhu, J. Zheng, D. Mou, J. Wan, J. Zhang, T. Shi, Y. Zhao, H. Xu, X. Yang,Iontophoresis-driven penetration of nanovesicles through microneedle-induced skinmicrochannels for enhancing transdermal delivery of insulin, Journal of controlled release :official journal of the Controlled Release Society, 139 (2009) 63-72.
[26] A.V. Badkar, A.M. Smith, J.A. Eppstein，A.K. Banga, Transdermal delivery of interferonalpha-2B using microporation and iontophoresis in hairless rats, Pharmaceutical research, 24(2007) 1389-1395.
[27] A. Pattani, P.F. McKay, M.J. Garland, R.M. Curran, K_ Migalska, C.M. Cassidy, R.K.Malcolm, R.J. Shattock, H.O. McCarthy, R.F. Donnelly, Microneedle mediated intradermaldelivery of adjuvanted recombinant HIV-1 CN54gpl40 effectively primes mucosal boostinoculations，Journal of controlled release ; official journal of the Controlled Release Society,162 (2012) 529-537.
[28] K. van der Maaden, W. Jiskoot, J. Bouwstra, Microneedle technologies for (trans)dermal drugand vaccine delivery, Journal of controlled release : official journal of the Controlled ReleaseSociety, 161 (2012) 645-655.
[29] Y.C. Kim, PJ. Ludovice，M.R. Pramnitz, Transdermal delivery enhanced by maininpore-forming peptide，Journal of controlled release : official journal of the ControlledRelease Society, 122 (2007) 375-383.
[30] J.B. Rothbard, S. Garlington, Q. Lin, T. Kirschbeig, E. Kreider, RL. McGrane, P.A. Wender,P.A. Khavari, Conjugation of arginitie oligomers to cyclosporin A facilitates topical deliveryand inhibition of inflammation. Nature medicine，6 (2000) 1253-1257.
[31] Y. Yang, R. Ou, S. Guan, X. Ye, B. Hu，Y. Zhang，S. Lu，Y. Zhou, Z. Yuan, J. Zhang, Q.G. Li,A novel drug delivery gel of terbinafine hydrochloride with high penetration for external use.Drug delivery, (2014).
[32] H. Chen, Y. Guan, Q. Zhong, Microemulsions Based on a Sunflower Lecithin-Tween 20Blend Have High Capacity for Dissolving Peppermint Oil and Stabilizing Coenzyme Q，Journal of agricultural and food chemistry, (2015)
[33] P.K, Ghosh，R.S. Murthy, Microemulsions: a potential drug delivery system, Current drugdelivery, 3 (2006) 167480.
[34] H.C. Vadlamudi, H. Narendran, T. Nagaswaram, G. Yaga, J, Thaimini, P.R. Yalavarthi,Microemulsions based transdermal drug delivery systems, Current drug discoverytechnologies, 11 (2014) 169-180.
[35] S. Duangjit, Y. Obata, H. Sano, Y. Onuki, P. Opanasopit, T. Ngawhirunpat, T. Miyoshi, S.Kato，K. Takayama, Comparative study of novel ultradeformable liposomes: menthosomes,transfersomes and liposomes for enhancing skin permeation of meloxicam, Biological &pharmaceutical bulletin, 37 (2014) 239-247.
[36] F. S. Guo，Y. Gan, X. Zhang, Preparation of redispersible liposomal dry powder using anultrasonic spray freeze-drying technique for transdermal delivery of human epithelial growthfactor. International journal of nanomedicine, 9 (2014) 1665-1676.
[37] F, Milletti, Cell-penetrating peptides; classes, origin, and current landscape, Drug discoverytoday, 17 (2012) 850-860.
[38] J.J. Turner, S. Jones, MM. Fabani, G. Ivanova, A.A. Arzumanov, MJ. Gait, RNA targetingwith peptide conjugates of oligonucleotides, siRNA and PNA，Blood cells, molecules &diseases, 38 (2007) 1-7.
[39] A.D. Frankel, C.O. Pabo，Cellular uptake of the tat protein from human immunodeficiencyvirus, Cell, 55 (1988) 1189-1193.
[40] C. Rudolph, C. Plank, J. Lausier, U. Schillinger, R.H. Muller, J. Rosenecker, Oligomers of thearginine-rich motif of the HIV-1 TAT protein are Capable of transferring plasmid DNA intocells, The Journal of biological chemistry, 278 (2003) 11411-11418.
医学硕士论文参考文献三
1. Altenbach, A., J.M. Bemhard, and J. Seckbach, Anoxia: evidence for eukaryote survival andpaleontological strategies. Vol. 21. 2011: Springer.
2. Polge, C.，A.U. Smith, and A.S. Parkes, Revival of Spermatozoa after Vitrification andDehydration at Low Temperatures. Nature, 1949.164(4172): p. 666-666.
3. Smith, A.U., Prevention of Haemolysis during Freezing and Thawing of Red Blood-Cells.Lancet, 1950.259(Dec30): p. 910-911.
4. Lovelock, J.E. and M,W.H. Bishop, Prevention of Freezing Damage to Living Cells byDimethylSulphoxide. Nature, 1959.183(4672): p. 1394-1395.
5. Mazur, R，S.P. Leibo，and E.H.Y. Chu, 2-Factor Hypothesis of Freezing Injury - Evidencefrom Chinese-Hamster Tissue-Culture Cells, Experimental Cell Research, 1972. 71(2); p,345.
6. Fahy, GM., D.R. Macfarlane, C.A. Angell, and H.T. Meryman, Vitrification as an Approachto Cryopreservation. Cryobiology, 1984. 21(4): p. 407-426.
7. Rail, W.F. and G.M. Fahy, Ice-Free Cryopreservation of Mouse Embryos at -19&Degrees-Cby Vitrification. Nature, 1985. 313(6003): p. 573-575.
8. Baust, J.，R. Van Buskirk, and J. Baust, Cryopreservation outcome is enhanced byintracellular'type medium and inhibition of apoptosis. Cryobiology, 1998. 37(4): p. 410-411.
9. Baust, J.M.，R. Van Buskirk, and J.G. Baust, Cell viability improves following inhibition ofcryopreservation-induced apoptosis. In Vitro Cellular & Developmental Biology-Animal,2000. 36(4): p. 262-270.
10. Baust, J.M.，M.J. Vogel，R. Van Buskirk，and J.G. Baust, A molecular basis ofI.cryopreservation failure and its modulation to improve cell survival Cell Transplantation,2001.10(7); p. 561-571.
11. Baust，J.M., R- Van Buskirk, and J.G. Baust, Modulation of the cryopreservation cap:elevated survival with reduced dimethyl sulfoxide concentration. Cryobiology，2002. 45(2); p.97-108.
12. Baust, J.M.，R. Van Buskirk’ and J.G. Baust, Gene activation of the apoptotic caspasecascade following cryogenic storage. Cell Preservation Technology, 2002.1(1): p. 63-80.
13. Gao, D” P. Mazur, and J. Critser, Fundamental cryobiology of mammalian spermatozoa.Reproductive Tissue Banking. Academic Press, New York，1997: p. 263-328.
14. Southard, J.H., T.M. Vangulik, M.S. Ametani, P.K. Vreugdenhil, S.L. Lindell, B.L. Pienaar,and F.O. Belzer, IMPORTANT COMPONENTS OF THE UWSOLUTION. Transplantation,1990. 49(2): p. 251-257.
15. Southard, J.H. and RO. Belzer, ORGAN PRESERVATION. Annual Review of Medicine,1995. 46: p. 235-247.
16. Taylor, M.J.，L.H. Campbell, R.N. Rutledge, and K.G.M. Brockbank, Comparison of Unisolwith Euro-Collins solution as a vehicle solution for cryoprotectants. TransplantationProceedings，2001. 33(1-2): p. 677-679.
17. Lovelock, J.E., THE HAEMOLYSIS OF HUMAN RED BLOOD-CELLS BY FREEZING ANDTHAWING Biochimica Et Biophysica Acta, 1953.10(3); p. 414-426.
18. Van Buskirk, R.G., J.M. Baust, K,K. Snyder, A.J. Mathew, and J.G. Baust, Hypothermicstorage and cryopreservation. Bioprocess International, 2004.
19. Taylor, M.J., Y.C. Song, and K.G. Brockbank, 22 Vitrification in Tissue Preservation: NewDevelopments. 2004.
20. Fahy, G.M., B. Wowk, R. Pagotan, A. Chang, J. Phan, B. Thomson, and L. Phan, Physicaland biological aspects of renal vitrification. Organogenesis, 2009. 5(3): p. 167-175.
21. Baust, J.G. and J.M. Baust, Advances in biopreservation. 2010: CRC Press.
22. Gao, D. and J. Critser, Mechanisms of cryoinjury in living cells. ILAR journal, 2000. 41(4): p.187-196.
23. Mazur, P. and K.W. Cole, INFLUENCE OF CELL CONCENTRATION ON THECONTRIBUTION OF UNFROZEN FRACTION AND SALT CONCENTRATION TO THESURVIVAL OF SLOWLY FROZEN HUMAN-ERYTHROCYTES. Cryobiology, 1985. 22(6): p.509-536.
24. Tani, M. and J.R. Neely, ROLE OF INTRACELLULAR NA+ IN CA-2+ OVERLOAD ANDDEPRESSED RECOVERY OF VENTRICULAR-FUNCTION OF REPERFUSED ISCHEMICRAT HEARTS - POSSIBLE INVOLVEMENT OF H+-NA+ AND NA+-CA2 EXCHANGE.Circulation Research, 1989. 65(4): p. 1045-1056.
25. Renlund, D.G., G. Gerstenblith, E.G. Lakatta, W.E. Jacobus, C.H. Kallman, and ML.Weisfeldt, PERFUSATE SODIUM DURING ISCHEMIA MODIFIES POST-ISCHEMICFUNCTIONAL AND METABOLIC RECOVERY IN THE RABBIT HEART Journal ofMolecular and Cellular Cardiology, 1984. 16(9): p. 795-801.
26. Neely, J.R. and L.W. Grotyohann, ROLE OF GLYCOLYTIC PRODUCTS IN DAMAGE TOISCHEMIC MYOCARDIUM - DISSOCIATION OF ADENOSINE-TRIPHOSPHATELEVELS AND RECOVERY OF FUNCTION OF REPERFUSED ISCHEMIC HEARTS.Circulation Research，1984. 55(6): p. 816-824.
27. Southard, J.H., N.C. Vanderlaan, M. Lutz, GS. Pavlock, J.R Belzer, and F.O. Belzer,COMPARISON OF THE EFFECT OF TEMPERATURE ON KIDNEY CORTEXMITOCHONDRIA FROM RABBIT, DOG, PIG, AND HUMAN - ARRHENIUS PLOTS OFADP-STIMULATED RESPIRATION. Cryobiology, 1983. 20(4): p. 395-400.
28. Nedergaard, J. and B. Cannon，MAMMALIAN HIBERNATION. Philosophical Transactionsof the Royal Society of London Series B-Biological Sciences, 1990. 326(1237): p. 669-686.
29. Brown, R.T. and J.G. Baust, Time course of peripheral heterothermy in a homeotherm. Am JPhysiol，1980. 239: p. R126-R129.
30. Lyons，J.M, and J.K. Raison，TEMPERA WRE-INDUCED TRANSITION INMITOCHONDRIAL OXIDATION - CONTRASTS BETWEEN COLD ANDWARM-BLOODED ANIMALS. Comparative Biochemistry and Physiology, 1970. 37(3): p.405.
31. Raison, J.K., INFLUENCE OF TEMPERATURE-INDUCED PHASE CHANGES ONKINETICS OF RESPIRATORY AND OTHER MEMBRANE-ASSOCIATEDENZYME-SYSTEMS, Journal of Bioenergetics, 1973. 4(1-2): p. 285-309.
32. Ricciutt.Ma, LYSOSOMES AND MYOCARDIAL CELLULAR INJURY. American Journal ofCardiology, 1972. 30(5): p. 498.
33. Weglicki, W.B.，K. Owens, R.C. Ruth, and Sonnenbl.Eh, ACTIVITY OF ENDOGENOUSMYOCARDIAL LIPASES DURING INCUBATION AT ACID PH. Cardiovascular Research,1974. 8(2): p. 237-242.
34. Liu, X., R.M. Engelman, J.A. Rousou, D.K. Das，and D. Das, Myocardial reperfusion injuryduring adult cardiac surgery. 1993: CRC Press，Boca Raton.
35. Dejong，J.W.，CARDIOPLEGIA AND CALCIUM-ANTAGONISTS - A REVIEW. Annals ofThoracic Surgery, 1986. 42(5): p. 593-598.
36. Schwertz, D.W., J. Halverson, T. Isaacson, H. Feinberg, and J.W. Palmer, ALTERATIONS INPHOSPHOLIPID'METABOLISM IN THE GLOBALLY ISCHEMIC RAT-HEART -EMPHASIS ONPHOSPHOINOSITIDE SPECIFIC PHOSPHOLIPASE-C ACTIVITY. Journalof Molecular and Cellular Cardiology, 1987.19(7): p, 685-697.
37. White, B.C., J.G Wiegenstein, and C.D. Winegar, BRAIN ISCHEMIC ANOXIA -MECHANISMS OF INJURY. Jama-Journal of the American Medical Association, 1984.251(12): p. 1586-1590.
38. Jennings, R. and C.E. Ganote, Structural changes in myocardium during acute ischemia.Circulation Rese^ch, 1974. 35: p. 156.
39. Jennings, R.B. and C.E. Ganote, MITOCHONDRIAL STRUCTURE AND FUNCTION INACUTE MYOCARDIAL ISCHEMC-INJURY, Circulation Research, 1976. 38(5): p. 80-91.
40. Clarke, D.M.，J.M. Baust，R.G Van Buskirk, and J.G. Baust, Addition of anticancer agentsenhances freezing-induced prostate cancer cell death: implications of mitochondrialinvolvement. Cryobiology，2004. 49(1): p. 45-61.